Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Jingjing Fu, Jun Zhao, Xiaochun Zhang, Xuesong Li, Li Xiaoming and Lin Zhang
Aim: To explore if gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MRI provides more accurate information than multi-detector row computed tomography (MDCT) for staging hepatocellular carcinoma (HCC).
Methods: We retrospectively investigated 112 patients with HCC who underwent MDCT and Gd-EOB-DTPA enhanced MRI within one month before treatment. Two experienced radiologists reviewed the size, number, and boundaries of the HCC lesions, portal invasion, and tumor metastasis on MDCT and MRI images in consensus. Then the performance of Gd-EOB-DTPA-enhanced MRI and MDCT on staging HCC lesions was compared through statistical analysis. The classification of the Barcelona Clinic Liver Cancer (BCLC) stage was also evaluated.
Results: HCC lesions in five patients were detected on Gd-EOB-DTPA-enhanced MRI only. Of the other 107 patients, 21 (19.6%) were in BCLC stage 0, 49 (45.8%) in BCLC stage A, 14 (13.1%) in BCLC stage B, and 23 (21.5%) in BCLC stage C on MDCT. On Gd-EOB-DTPA-enhanced MRI, 12 (11.2%), 48 (44.9%), 17 (15.9%), and 30 (28.0%) patients were classified as BCLC stages 0, A, B, and C, respectively. The two methods differed significantly in staging HCC patients (χ2=16.444, P=0.006).
Conclusion: This study suggests that Gd-EOB-DTPA-enhanced MRI provides more accurate information than MDCT for characterizing and staging HCC which will help to choose accurate treatment strategy.